Description du projet
Améliorer le contrôle de la fièvre de Lassa au Nigeria
La fièvre de Lassa (FL) est une maladie grave dont le taux de mortalité est élevé parmi les patients hospitalisés en Afrique de l’Ouest. Il n’existe actuellement aucun traitement sûr et efficace de la FL, à l’exception de la ribavirine, que certains experts remettent en question. Un traitement efficace permettrait de réduire le taux de mortalité et d’atténuer les conséquences socio-économiques. Le Nigeria est le pays le plus touché par la FL, avec 80 % des cas recensés dans le monde. Le projet INTEGRATE, financé par l’UE, se propose d’établir une plateforme d’essais cliniques afin d’évaluer de nouveaux médicaments, et d’autres qui ont été repositionnés, au Nigeria et dans d’autres pays touchés par la maladie. En facilitant le transfert de technologie et la formation, à la fois entre le nord et le sud et entre les différents pays du sud, le projet ambitionne de renforcer la capacité des sites, des laboratoires et des établissements de soins médicaux.
Objectif
Lassa fever (LF) is an acute febrile illness associated with bleeding, organ failure, and shock caused by Lassa virus. LF causes outbreaks in West African with in-hospital mortality up to 12%. Challenges in the clinical care of patients are multiple due to the limited availability of LF molecular diagnostics, the risk for nosocomial transmission, and the limited treatment options.There are currently no safe and effective treatment options available for LF, except ribavirin, the efficacy of which is debated. The clinical development and accessibility of effective treatment options would be a game-changer towards reducing mortality associated with this disease and limiting its socio-economic impact. Nigeria is the country by far most affected by LF in the world with about 80% of global cases.
The INTEGRATE consortium builds on a more than 15 years lasting highly successful collaboration between leading European and West African institutions focusing on the joint priority to better understand, manage, and combat LF in West Africa.
The overall objective of the INTEGRATE project is to establish a GCP-compliant adaptive clinical platform trial in West Africa (Nigeria and other countries) to test the efficacy, tolerability and safety of repurposed and novel drug candidates for the treatment of LF. To address this objective, we focus our activities on 3 specific objectives:
- to develop and implement an adaptive randomised controlled phase II-III clinical platform trial evaluating drugs with proven preclinical activity against LF.
- to build capacity for sustainable and independently conducted clinical research in West Africa by developing site, laboratory and medical care capacity through North-South and South-South technology transfer and training. This activity encompasses capacity building of the lead Nigerian institution in GCP compliant clinical trial sponsorship.
- to engage communities with the proposed work plan and to assess acceptability of the trial.
Champ scientifique
Programme(s)
- HORIZON.2.1 - Health Main Programme
Régime de financement
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinateur
33000 Bordeaux
France